Early trials of the Oxford-AstraZeneca vaccine against COVID-19 show that it provides minimal protection against new strains of the virus that have been detected in South Africa.
Preliminary results were first reported by the Financial Times and confirmed by AstraZeneca.
According to the results, the vaccine provides minimal protection against weak and moderate levels of the virus.
However, the company says it believes the vaccine could protect people against a serious illness caused by the new strain of the virus.
Preliminary results from a study of more than 2,000 people have not yet been evaluated by experts.
More than 100 different cases of the new strain of the virus have been detected in the UK.
.
The Oxford-AstraZeneca vaccine provides only limited protection against a new type of crown virus – Radio National
